Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2022

View Archived Issues

CD14 associated with poor cognitive function in survivors of testicular germ-cell tumors

Lipidated IL-22 ameliorates colon inflammation in preclinical colitis model

Study shows how gut-derived metabolites enter the brain and affect behavior

IBD-3540, a novel gut-restricted GCPII inhibitor with oral preclinical activity in models of colitis

Shaanxi Synthetic Pharmaceutical divulges new antiarthritic drugs

Guangzhou Henovcom Bioscience discloses new antivirals

T2YC presents new integrin modulators

IFM Due synthesizes new hSTING antagonists

Institute of Medicinal Biotechnology presents new androgen receptor antagonists

Targeting of CRYAB with 25-hydroxycholesterol induces kills senescent cells in vitro and in vivo

AU-011 shows promising binding and tumor distribution in models of urothelial neoplasia

DNA methylation mediated by METTL3-METTL14 complex is largely restricted by structured RNA elements

CD70 identified as promising therapeutic target in advanced RCC

Moderna announces new mRNA vaccine candidates for HSV, VZV and cancer

SIGMAR1 targeting ameliorates preclinical Wolfram syndrome symptoms

GR-3027 reverses neuroinflammation in rat model of hyperammonemia

"Twin study" of sorts brings insight into arthritis microbiome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...